Email ID
Password
Scrip   
GSK to market Amgen's denosumab for osteoporosis
28 July 2009
Sita Shah

GlaxoSmithKline is to commercialise Amgen's investigational monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe and various other countries, including emerging markets. The antibody (Prolia is the proposed trade name) is also indicated for cancer, to which Amgen retains the...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36